JAK2 and prostate cancer: Our results were consistent with a recent study which documented that in ccRCC, miR-187 targeted CD276 and decreased the CD276 mRNA expression.14 Similarly, the results obtained from a study also proved that upregulation of CD276 resulted in activation of the JAK2-STAT3-Slug pathway in HCC.19 Therefore, it can be concluded that the miR-187 inactivates the JAK3-STAT3-Slug pathway by targeting CD276 in prostate cancer.